Call for submissions (new format available):JLB’s COVID19 and Related Topics Special Initiative
Email with QuestionsSubmit to JLBHelp Spread the word by sharing this call for papers PDF Types of submissions accepted for COVID–19 and Related Topics Special Initiative include:
Pathway to publication: Articles submitted will undergo preliminary review by a COVID–19 Task Force selected from SLB members, the editorial board, and chaired by the Editor-in-Chief. All submissions must include a cover letter and address the following questions:
Criteria for selection to be applied by the COVID–19 Task Force for peer review will be based on the following:
Submitted articles will need to achieve a “yes” answer to first two criteria and a “more likely than not” answer to the last two criteria to qualify for review. An expedited peer review will be conducted, with a decision of “accept”, “accept with minor revisions”, or “reject” rendered within 14–21 days. Accepted articles will be published by open access immediately online as part of the JLB COVID–19 and related topics collection. Rejected articles may be reconsidered as new submissions if substantial additional data or updates are added.
Fees: All articles accepted will be published as ‘free to read’ with no charge to the authors (publication fees still apply: $1,700 for SLB members, $1,950 for non-members). Articles will be accepted until December 31, 2021 JLB COVID-19 and Related Topics Task Force Luis J. Montaner, Editor-In-Chief, Professor, The Wistar Institute, Dong-Yan Jin, Professor, The University of Hong Kong, Jean Scholz, Sr. Res. Investigator, University of Pennsylvania, Yufang Shi, Professor, Soochow University, Jiangsu, China Jamie Sturgill, Assistant Professor, University of Kentucky, David Weiner, Professor, The Wistar Institute, Lilin Ye, Professor, Third Military Medical University, Chongqing, China |
On February 11, 2020, The World Health Organization officially announced the emergence of a novel virus, SARS-CoV–2, as the causative agent of COVID–19. Four weeks later a global pandemic was formally declared. In keeping with the mission of the Journal of Leukocyte Biology, we are launching the COVID–19 and Related Topics Special Initiative to create an expedient and open access publication track to quickly publish leukocyte biology-related research to advance our understanding of host pathophysiology and defense/resistance against disease. Submissions for this collection will be accepted until December 31, 2021. The accepted manuscript will be published online immediately after decision is made.
Articles may be hypothesis-based or hypothesis-generating, with a review of relevant literature and/or new data. Research may feature novel basic, animal model, or translational-based findings. All research should advance our understanding of disease processes, with focus on affected organs systems impacted by this virus. Authors must tie topics investigated to leukocytes or other cells that fall within the scope of JLB. The information presented and conclusions offered need to be clear enough to be cited. The central objective is that the data presented, or hypotheses generated, will move the field toward future experiments and improve our understanding of the pathogenesis, immunology, and resolution of COVID–19 and related diseases.
Accepted articles:
